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Abstract
Haploinsufficiency in DYRK1A is associated with a recognizable developmental syndrome, though the mechanism of action
of pathogenic missense mutations is currently unclear. Here we present 19 de novo mutations in this gene, including five
missense mutations, identified by the Deciphering Developmental Disorder study. Protein structural analysis reveals that the
missense mutations are either close to the ATP or peptide binding-sites within the kinase domain, or are important for pro-
tein stability, suggesting they lead to a loss of the protein’s function mechanism. Furthermore, there is some correlation be-
tween the magnitude of the change and the severity of the resultant phenotype. A comparison of the distribution of the
pathogenic mutations along the length of DYRK1A with that of natural variants, as found in the ExAC database, confirms that
mutations in the N-terminal end of the kinase domain are more disruptive of protein function. In particular, pathogenic mu-
tations occur in significantly closer proximity to the ATP and the substrate peptide than the natural variants. Overall, we sug-
gest that de novo dominant mutations in DYRK1A account for nearly 0.5% of severe developmental disorders due to substan-
tially reduced kinase function.
Introduction
The DYRK1A protein is a member of the highly conserved dual-
specificity tyrosine-phosphorylation-regulated kinase (DYRK)
family, which also includes the human members DYRK1B,
DYRK2, DYRK3, and DYRK4 (1). Like all DYRK members,
DYRK1A contains a conserved catalytic kinase domain preceded
by a characteristic DYRK homology (DH) box, see Fig. 1. It also
contains two nuclear localization signals (NLS), one prior to and
one within the kinase domain, a PEST domain, a speckle-
targeting signal (STS), a histidine repeat and a serine/threonine
repeat (2). Although part of a Ser/Thr kinase family, the protein
autophosphorylates the second tyrosine (Tyr321) of the activa-
tion loop YxY motif during translation. The tyrosine phosphor-
ylation ability is lost once the protein is fully folded whereas the
serine/threonine phosphorylation ability is retained (3–5).
The DYRK1A gene is located on chromosome 21 in the Down’s
syndrome (DS) critical region, associated with the development
of DS phenotypes when triplicated (6–10). In Drosophila the
DYRK1A orthologue plays an essential role in neurogenesis, with
mutant flies having a reduced brain size (1,11). Similarly, mice
with only one functional copy of the gene have brains 30%
smaller than those of wild type mice; moreover, mutations in
mice also result in intrauterine growth restriction, behavioural
defects and altered motor activity due to dopaminergic dysfunc-
tion (12–14). More recently, haploinsufficiency of DYRK1A in
humans has been shown to cause intellectual disability, global
developmental delay, microcephaly, intrauterine growth restric-
tion, dysmorphic facial features, speech delay/absence, autism,
febrile seizures, ocular malformations (15–27). Tejedor and
Hammerle (10) reviewed the role of DYRK1A in neuronal develop-
ment and characterized the protein as a regulator of a broad spec-
trum of neurodevelopmental mechanisms, listing many possible
substrate and/or interacting proteins. A more recent study
showed the protein is also recruited to promoters of genes ac-
tively transcribed by RNA polymerase II (RNAPII) after which it
phosphorylates the C-terminal domain of RNAPII (28).
Unfortunately, very little is known about its physiological sub-
strate or interacting partners in neuronal development.
To date, only a handful of missense mutations in this gene
have been associated with developmental phenotypes. The
mechanism by which they cause disease is therefore unclear. Ji
et al. analysed three missense mutations and observed that
they occur in close proximity to the ATP binding site, which
could account for their disruptive effect (26). Here we describe
19 new mutations, including five missense, as found in children
in the Deciphering Developmental Disorder (DDD) Study (21),
being children with previously undiagnosed severe develop-
mental disorders. We analyse the locations of the missense mu-
tations on the protein’s 3D structure to assess their likely
impact on its stability and function. We also examine other mu-
tations reported in the literature (29) and compare them with
population variants obtained from the Exome Aggregation
Consortium (ExAC) database (30).
Results
An analysis of 4,293 family trios from the DDD study identified
nineteen children as having likely pathogenic de novo mutations
in DYRK1A (31). This corresponds to around 0.44% of those
analysed (0.52% having intellectual disability). The mutations
are listed in Table S1 with detailed patient phenotypes. Their lo-
cations are mapped onto the protein sequence in Fig. 1. All 19
patients have an intellectual disability and some dysmorphic
facial features, 18 have microcephaly and restricted growth, 14
have eye malformations or visual impairments (including
deeply set eyes, retinal dystrophy, optic atrophy, astigmatism,
amblyopia, iris coloboma, bilateral microphthalmos, retinal de-
tachment, hypermetropia and early cataracts), 11 have abnor-
mal MRI scans, and 8 have seizures. A summary of quantitative
phenotypes in these patients taken directly from the DECIPHER
database (32) (https://decipher.sanger.ac.uk/gene/DYRK1A#over
view/clinical-info) is shown in Fig. 2; one patient (DECIPHER ID
273659) is excluded as the database is unable to accept inver-
sions at this time. Only one patient (DECIPHER ID 265726) does
not have microcephaly, which is likely explained by an add-
itional diagnostic de novo mutation in TNNI2, resulting in a com-
plex compound phenotype.
In our cohort, all 14 protein disrupting mutations (including six
frameshift, two splice-site, five stop-gained and a 20kb intragenic
inversion) occur before the C-terminal end of the kinase domain,
so are likely to result in nonsense-mediated decay and complete
loss of protein, rather than a truncated protein product. The five
missense mutations all occur within the kinase domain, and their
3D locations are shown in Fig. 3. Each is described in turn below.
The missense DDDmutations
The first is Leu207Pro which is located in an a-helix close to the
ATP-binding pocket (Fig. 3). The replacement of this leucine by a
proline will either break or kink the helix. Prolines are known as
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‘helix breakers’ for two reasons: the side chain sterically inter-
feres with the backbone of the preceding turn and the backbone
nitrogen is unable to participate in backbone hydrogen bonds
that stabilize a-helices. Moreover, according to the HSSP align-
ments, the leucine at this position is highly structurally con-
served (99%); the only other amino acid observed at this
position is the similar valine. Leu207 is highly buried – its ac-
cessible surface area (ASA) is 0.0, as calculated by the NACCESS
program (33). This means it occupies a very specific space that a
very different residue, such as a proline, would be incapable of
filling. Hence it seems likely that the mutation will result in a
conformational change affecting the ATP-binding pocket and
disrupting the interactions necessary for the protein’s enzym-
atic activity. The patient with this mutation (DECIPHER ID
259211) has an intellectual disability with severe microcephaly
(4.3 SD) and growth restriction, as well as seizures, astigma-
tism and amblyopia, all in keeping with the haploinsufficiency
syndrome previously described.
The second mutation, Ala277Pro, occurs on the surface of the
protein immediately after an a-helix, in a loop in close proximity
to the catalytic loop (Fig. 3). As for the first mutation above, the re-
placement by a proline is potentially problematic for the helix, al-
though this residue is not strongly structurally conserved (13%
alanine, 36% histidine, 11% lysine, 10% arginine). The entire loop
that contains Ala277 is not structurally conserved, suggesting it is
structurally and functionally of low importance. The / backbone
torsion angle of Ala277 is 81 whereas proline has a fixed /-
angle of around 65 (34) – so not too dissimilar. Thus, it is not
clear why this mutation should result in the phenotype, since
such a small change in the torsion angle could be compensated
by minor angle changes in the rest of the loop. However, the
backbone of the entire loop seems fairly stable. For example, in
one of the highest-resolution structures of this kinase domain
(PDB code 4ylk, solved at 1.4A˚) the loop has a low ‘temperature-
factor’ (between 8 and 13) together with a well-defined electron
density. This indicates low flexibility. It is possible that the mu-
tation disrupts the overall stability of the domain and, given its
proximity to the catalytic loop, alters the structure around the
catalytic loop, reducing its catalytic efficiency. In support of
this, the patient (DECIPHER ID 267221) has an intellectual dis-
ability with microcephaly (3.3 SD) and growth restriction, as
well as delayed speech and language development and retinal
dystrophy.
The deleterious effect of the third mutation, Asp287Val, is
the most straightforward to explain as Asp287 is a catalytic
residue directly involved in the reaction with the substrate;
mutation to valine eliminates the catalytic ability of the pro-
tein. This amino acid is 100% conserved and also has import-
ant interactions with other conserved residues such as a
hydrogen bond with Ser324 and a salt bridge to Lys289. Figure
3 shows the residue’s location and interactions. The affected
patient (DECIPHER ID 258963) has an intellectual disability
with severe microcephaly (4.8 SD) and growth restriction, as
well as delayed speech and language development and early
cataracts.
The Ser346Pro mutation has previously been observed in
two patients with a similar phenotype (15), although no struc-
tural analysis has been performed before. The residue is located
in the middle of an a-helix and the side-chain forms three
hydrogen bonds, one of which is with the side chain of Gln323
in the activation loop, see Fig. 3. This residue is highly structur-
ally conserved (99% serine, 1% alanine), suggesting it plays an
important role in the stability of the protein. Even though the
backbone nitrogen does not form a hydrogen bond, replacement
by a proline might, as in previous cases described above, be
catastrophic for the stability of the a-helix. The patient
(DECIPHER ID 260956) has an intellectual disability with very se-
vere microcephaly (7.3 SD) and growth restriction, as well as
seizures.
Finally, the Arg467Gln mutation is the most distal patho-
genic mutation in our cohort, far from the substrate and ATP-
binding pocket, being in a loop near the C-terminal end of the
kinase domain. The residue is part of a network of electrostatic
interactions, as shown in Fig. 3, and is expected to play an im-
portant role in the overall stability of the protein. Only arginine
is capable of forming all these interactions and is the only
amino acid that can fit into this specific space. Furthermore, it is
100% structurally conserved. Changing it to glutamine would
likely disrupt the stability of the protein’s fold, although pos-
sibly not the structure of the catalytic or ATP-binding sites.
Thus, it might reduce the efficiency of the kinase rather than
eliminating it completely. Accordingly, the patient (DECIPHER
ID 2701740) appears to have the least severe phenotype of the
cohort, with intellectual disability, mild microcephaly (2.3 SD)
and truncal obesity.
Other DYRK1Amutations
We then compared the locations of the known missense patho-
genic mutations in DYRK1A (five from this study and six from
Figure 1. Domain arrangement of DYRK1A with location of diagnostic mutations. The kinase domain is enlarged and the catalytic loop and activation loop are labelled.
NLS, nuclear localization signal; DH, DYRK homology box; PEST, proline, glutamic acid, serine, and threonine rich domain; STS, speckle-targeting signal; H, histidine re-
peat; S/T, serine/threonine repeat. Missense mutations are shown beneath the domain diagram, with position and amino acids; protein truncating variants are show
above the diagram (*¼ stop-gained; lightning-bolt¼ frameshift; star¼ splice site; arrow¼ inversion). Arg437 to a stop codon occurred twice in the dataset.
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the literature (15,25,26)) on the 3D structure of the protein with
the locations of natural, non-disease-associated variants listed
in ExAC (Fig. 4). The gene is highly constrained, but the distribu-
tions of the two sets of variants are quite different, with most of
the natural ones found either prior to the first nuclear localiza-
tion signal or after the kinase domain (Fig. 4A). The natural vari-
ants in the kinase domain are mostly located at the C-terminal
end whereas most of the pathogenic mutations occur in the
N-terminal half, supporting the notion that the mutational bur-
den is overall higher in this region. Figure 4B shows the 3D loca-
tions of the pathogenic mutations (magenta) and the population
variants (grey). The former cluster around the ATP and peptide,
whereas the latter tend to lie further away, and particularly in
the C-terminal (lower) part of the domain. The boxplot in Fig. 4C
shows the closest distances of each of the variants from either
the ATP or the bound peptide, or from one or the other. In all
three cases, the disease-causing mutations are significantly
closer to the bound molecule than the population variants
(Wilcoxon-Mann-Whitney test: P¼ 0.001, P¼ 0.01 and P¼ 0.008
for ATP, peptide and the closest of the two, respectively).
The mutation effect prediction program SIFT (35) predicted
all disease-associated mutations within the kinase domain to
be deleterious but predicted the Thr588Asn mutation from a
previous study (which lies outside the domain) to be non-
deleterious. Of the 171 natural variants, 112 were predicted to
be non-deleterious, 32 to be damaging with a low confidence
interval and 27 were predicted to be deleterious of which 21
occurred in the kinase domain. These results underline the im-
portance of the kinase domain.
Discussion
We have described 19 pathogenic de novo dominant mutations
in DYRK1A, taking the total number of mutations described in
the literature to over 70. Pathogenic sequence mutations in
this gene result in loss of protein function and account for
around 0.5% of syndromic intellectual disability. Patients typ-
ically have global developmental delay and microcephaly
(average head circumference in our cohort¼4.6 SD) with a
number of other common phenotypes including delayed
speech and language, growth restriction, dysmorphic facial
features, eye malformations and seizures. The phenotypes
and molecular mechanisms described here are consistent with
haploinsufficiency.
Protein structural analysis of the missense mutations in our
cohort indicates that the affected residues are crucial for cata-
lytic function or stability of the DYRK1A kinase domain. The
phenotypic impact of some of the missense mutations appears
as severe as that of the loss-of-function mutations, suggesting
they may be disrupting the protein’s function as comprehen-
sively as the loss-of-function cases. Furthermore, there does ap-
pear to be some genotype-phenotype correlation, in that the
more severe phenotypes are seen when the missense variant is
closest to the catalytic loop or either of the substrate binding
sites. Analysis of the distribution of variation within the domain
structure of the protein is also informative with respect to other
mutations. Interestingly, while all the pathogenic splice site
mutations identified in this study occur within the kinase do-
main itself, which is likely to be intolerant to alternative splic-
ing, likely benign splice variants and indels occur either
Figure 2. Phenicon comparing quantitative phenotypes for patients with variants in DYRK1A in DDD with all patients in DECIPHER and normal developmental param-
eters (An updated version is available online at https://decipher.sanger.ac.uk/gene/DYRK1A#overview/clinical-info). The P-values of all phenotypes with significant dif-
ferences between the DYRK1A cohort and the DECIPHER cohort are shown below the plots.
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Figure 4. Analysis of pathogenic versus natural missense variations in DYRK1A. (A) Domain composition of DYRK1A (as in Figure 1) with the locations of the 171 natural
variants from ExAC plotted as a smoothed curve above it. The locations of the known pathogenic missense mutations are labelled below the domain diagram, with the mu-
tations from this study shown in red and mutations from the literature in grey (Ser346Pro occurs in both). (B) Ribbon diagram of the DYRK1A kinase domain (transparent),
taken from PDB entry 2wo6. The Ca position of pathogenic missense mutations shown as magenta sphere and natural variants as grey spheres. The green ball-and-stick
models represent ATP (top) and the substrate peptide (bottom). (C) Boxplot of the distance between the mutated residues in DYRK1A and the ATP or the substrate peptide.
ATP/Peptide gives the shortest distance to either the ATP or the peptide. The magenta filled points correspond to the five missense mutations from the DDD study.
Figure 3. Ribbon diagram of the kinase domain of DYRK1A (PDB entry 2wo6) with the Ca position of the five pathogenic missense mutations represented by gold
spheres. The activation and catalytic loop are illustrated by the purple and green loops, respectively. The ATP and substrate peptide are depicted as green ball-and-
stick models, where ATP is the smaller molecule. Each mutation has an inset to show the local environment of the mutated residue.
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proximal to the start of the N-terminus of the domain or distal
to the C-terminal end where alternatively spliced isoforms of
the protein may be viable. Similarly, benign in-frame inser-
tions/deletions both within ExAC and the DDD dataset also
occur distal to the kinase domain, where the addition or re-
moval of amino acids is unlikely to substantially alter the cata-
lytic efficiency of the protein. In vitro experiments could be
performed in future work to elucidate the effects of natural vari-
ants on the protein compared to the pathogenic variants. It
would be interesting to investigate whether these findings in
DYRK1A hold true for other kinases involved in disease.
Materials and Methods
The DDD study was approved by the UK Research Ethics
Committee (10/H0305/83, granted by the Cambridge South REC,
and GEN/284/12 granted by the Republic of Ireland REC), and ap-
propriate informed consent was obtained from all participants.
Patients meeting the recruitment criteria (neurodevelopmental
disorder and/or congenital anomalies, abnormal growth param-
eters, dysmorphic features and unusual behavioural phenotypes)
were recruited to the DDD study (www.ddduk.org) by their UK
NHS and Republic of Ireland Regional Genetics Service, who also
recorded clinical information and phenotypes using the Human
Phenotype Ontology (36) via a secure web portal within the
DECIPHER database (32). DNA samples from patients and their
parents were analysed by the Wellcome Trust Sanger Institute
using high-resolution microarray analysis (array-CGH and SNP-
genotyping) to investigate copy number variations in the child
and by exome sequencing to investigate single nucleotide vari-
ants and small insertions/deletions (indels). All genomic variants
were annotated with the most severe consequence predicted by
Ensembl Variant Effect Predictor (37) and their minor allele fre-
quencies observed in diverse population samples. As has been
described previously (38), likely diagnostic variants were commu-
nicated to referring clinical geneticists for validation in an ac-
credited diagnostic laboratory and discussion with the family via
patients’ record in DECIPHER, where they can be viewed in an
interactive genome browser.
Several Protein Data Bank (PDB) structures of the DYRK1A pro-
tein are available, all limited to the DH-box and kinase domain
(residues 137–479 of the protein). Here, we use PDB accession 4ylk
(39) to study the structural locations of the mutated residues. It
has the highest resolution and has been published most recently
of all the DYRK1A structures. We also used PDB accession 2wo6
(40), since this structure contains a bound substrate peptide. The
structures were analysed and figures were made using CCP4mg
(41). Structural conservation was extracted from the HSSP (hom-
ology-derived structures of proteins) database (42), which uses
194 sequences predicted to be structurally similar to PDB acces-
sion 4ylk. Population variants, 176 in total (171 missense), were
retrieved from Exome Aggregation Consortium (ExAC),
Cambridge, MA (URL: http://exac.broadinstitute.org) [date (April,
2016) accessed]. Because none of the available PDB structures of
DYRK1A is in complex with ATP, the distance between a mutated
residue and the bound ATP was estimated by taking the distance
between the residue and the ATP inhibitor. Distances were calcu-
lated by taking the shortest atom-atom distance between the
residue and the molecule of interest (the latter being either ATP
or the substrate peptide). The shortest distance to both ATP and
substrate peptide was also calculated.
Supplementary Material
Supplementary Material is available at HMG online.
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